A better drug is coming. I'm not sure who'll be able to afford it.

My first thought wasn't a careful one. It was just: wow, it's actually living up to the hype.

The retatrutide numbers are out, and they're the biggest the GLP-1 class has produced. In the Phase 3 trial, the top dose averaged about 28% of body weight lost over 80 weeks, roughly 70 pounds. A subgroup that kept going hit around 30% past the two-year mark and was still dropping. More than 45% of the people on that top dose lost at least 30% of their body weight, which is a number people usually attach to surgery, not a once-weekly shot.

I'm on tirzepatide. Right now tirzepatide is the best thing you can actually get with an FDA approval behind it. So it's a strange thing to sit with: the drug that looks like it's going to beat it, by a real margin, is also the one closest to the front of the line.

yeah, I felt the pull

I'm not going to pretend I read those numbers with pure scientific detachment. If there's a new best thing, part of me just wants the best thing. That's honest.

It's the same pull I wrote about with the pills. The oral options that came out aren't as good as tirzepatide, and that's exactly why I stayed on the shot. Retatrutide flips that math. If it comes out and it really is that much better, I'm going to feel some FOMO about not being on it.

But wanting the best thing and switching are not the same decision. I probably won't switch unless I have a reason. The reason I'd watch for is a stall. I don't think I'll hit one soon, I'm on a fairly low dose and still have room to climb, but if my own progress topped out, that's when retatrutide stops being interesting reading and starts being a real conversation. None of this is tomorrow. It may be a year or more before it's approved and actually available. So I have time to just watch.

There's a quieter thing the 30% number did for me, too. I've been losing faster than the tirzepatide trial average, partly because I've changed a lot besides the medication. I'm already getting close to that ~20% average, sooner than is typical, and a small part of me wonders if that means a plateau is coming. I don't really think it does. But knowing there's a more effective drug behind the current one makes me feel calmer about how much I still have to lose. If I ever top out on what I'm on, the ceiling isn't the ceiling anymore.

the catch isn't the science

Here's the part most of the headlines skip, and it's the part I can't stop thinking about.

Retatrutide is a peptide, and how the FDA classifies it decides how long it stays a monopoly. Treated as a regular small-molecule drug, the way tirzepatide is, you're looking at roughly five years before real competition can show up. Classified as a biologic, it's about twelve, and the copies of a biologic are far harder and slower to make than ordinary generics. Lilly has gone to court to get it called a biologic.

Nothing about that surprises me. Of course they want it. It would make the drug far more profitable, for far longer. That's the company doing what the company does.

But follow it out. If retatrutide lands as a biologic, the best obesity drug we've seen would also be the most expensive one, for the longest stretch, with the fewest cheaper alternatives. It would probably run into the same insurance walls these drugs already hit, or worse ones. Insurance is already a whole problem. Most plans still don't cover this, plenty of people are paying out of pocket, and out of pocket is not cheap. So the drug that could help the most people might be built, on purpose, to reach the fewest. I think that's a bad outcome for the whole healthcare picture, because I want more people to have access, not less.

There are other companies working on their own drugs, and competition usually drags prices down eventually. The catch is the word eventually. Nothing I've seen looks close. How long until real competition shows up is the actual question, and I don't have the answer.

what worries me more than the molecule

While retatrutide is the shiny future, the affordable present is getting harder to reach.

For a while, people could get compounded semaglutide and tirzepatide for a lot less than the brand. I've heard mixed things about what the latest crackdown actually changes, because some of it is just restating that compounders aren't supposed to make exact copies. A lot of pharmacies have been adding something like B6 or B12, or offering doses that don't match the strict options the manufacturer sells, and if that pathway stays open, the compounding world may not shrink as much as the headlines suggest. We'll see.

The cost gap is real and it's big. Compounded can run less than $200 a month. Going direct from the manufacturer is more like $400 to $450. That's over $200 a month, close to $2,500 a year. That's not a rounding error to most people, it's the difference between staying on the medication and not. And I don't buy the idea that every compounding pharmacy is a bad actor. There are legitimate ones, and for a lot of people they're the only version of this that's affordable.

So the thing I keep circling, the part I don't say out loud much: if compounding actually closed, it would be devastating for a lot of people. Even $200 a month is real money. If that disappears and the only door left is $450, some people are going to go looking for the gray market instead, ordering from sources with no pharmacy behind them. That's outside my own risk tolerance. But I understand exactly how someone gets pushed there, and a world where more people are doing that is a less safe one. The fix isn't lecturing people. It's insurance and manufacturers actually working to make this accessible, and right now they mostly aren't.

if you're reading the headlines and panicking

If you're on tirzepatide and you just saw a 30% number and felt your stomach drop, here's what I'd actually say.

If tirzepatide is working for you, hold onto that. I want the best drug too, all things equal. But tirzepatide is genuinely changing my life, and a better trial result somewhere else doesn't undo that. You are not on the wrong track because something newer exists. I'll look hard at retatrutide if and when it's approved. Until then I'm not worried, and I don't think you need to be either.

The other side: if you're someone the current drugs haven't worked well for, if the appetite quiet never really came, or you've tried both semaglutide and tirzepatide and neither did much, then I think this news is genuinely hopeful. More options getting approved means more chances that one of them fits you. A newer one might do what the last one couldn't. Having more doors is good for everybody, not just the people chasing the highest number.

What any of this means for your own treatment is a conversation for you and your doctor.

what I'm actually doing about it

Nothing.

I'm not changing my dose, my plan, or my timeline. The only thing this has cost me is hours, because I find what's happening in this industry genuinely fascinating and I keep reading about it. Tirzepatide is working. I'm watching the rest of it the way you watch weather that hasn't reached you yet: with real interest, and no umbrella out.